Head to Head Review: Coloplast A/S (OTCMKTS:CLPBY) and Vicarious Surgical (NYSE:RBOT)

Vicarious Surgical (NYSE:RBOT) and Coloplast A/S (OTCMKTS:CLPBY) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Vicarious Surgical and Coloplast A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-81.46%	-63.62%
Coloplast A/S	18.69%	30.19%	10.27%

Insider & Institutional Ownership

47.3% of Vicarious Surgical shares are held by institutional investors. 11.7% of Vicarious Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Vicarious Surgical and Coloplast A/S”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$71.07 million	($10.29)	-1.46
Coloplast A/S	$3.93 billion	N/A	$734.50 million	$0.33	32.76

Coloplast A/S has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Vicarious Surgical and Coloplast A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	0	2	0	0	2.00
Coloplast A/S	0	2	0	0	2.00

Vicarious Surgical currently has a consensus target price of $10.25, indicating a potential downside of 31.67%. Given Vicarious Surgical’s higher possible upside, equities research analysts clearly believe Vicarious Surgical is more favorable than Coloplast A/S.

Risk & Volatility

Vicarious Surgical has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.

Summary

Coloplast A/S beats Vicarious Surgical on 7 of the 11 factors compared between the two stocks.

About Vicarious Surgical

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.